

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Zai Lab Limited**  
**再鼎醫藥有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 9688)**

**OVERSEAS REGULATORY ANNOUNCEMENT — FORM 8-K**

This announcement is made by Zai Lab Limited (the “**Company**”) pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

On June 11, 2024 (U.S. Eastern Time)/June 12, 2024 (Shanghai and Hong Kong Time), the Company filed a Form 8-K with the U.S. Securities and Exchange Commission (the “**SEC**”) with respect to (i) the retirement of Dr. Harald Reinhart, President, Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases, effective June 30, 2024, and (ii) the expansion of the role of Dr. Rafael Amado, President, Head of Global Oncology Research and Development to President, Head of Global Research and Development, effective upon Dr. Reinhart’s retirement on June 30, 2024. There were no disagreements between Dr. Reinhart and the Company relating to the Company’s operations, policies, or practices that resulted in his decision to retire. For more details, please refer to the attached for the Form 8-K which has been published on the website of the SEC at [www.sec.gov](http://www.sec.gov) and our website at [www.zailaboratory.com](http://www.zailaboratory.com).

By order of the Board  
**Zai Lab Limited**  
**Samantha Du**

*Director, Chairperson and Chief Executive Officer*

Hong Kong, June 12, 2024

*As at the date of this announcement, the board of directors of the Company comprises Dr. Samantha Du as a director, and Dr. Kai-Xian Chen, Dr. John Diekman, Dr. Richard Gaynor, Ms. Nisa Leung, Mr. William Lis, Mr. Scott W. Morrison, Mr. Leon O. Moulder, Jr., Mr. Michel Vounatsos and Mr. Peter Wirth as independent directors.*

*\* For identification only*

---

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**  
**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): June 11, 2024**

---

**ZAI LAB LIMITED**

(Exact name of registrant as specified in its charter)

---

**Cayman Islands**  
(State or other jurisdiction of  
incorporation or organization)

**001-38205**  
(Commission  
File Number)

**98-1144595**  
(I.R.S. Employer  
Identification No.)

**4560 Jinke Road**  
**Bldg. 1, Fourth Floor, Pudong**  
**Shanghai, China**  
**314 Main Street**  
**4th Floor, Suite 100**  
**Cambridge, MA, USA**  
(Address of principal executive offices)

**201210**

**02142**  
(Zip Code)

**+86 21 6163 2588**

**+1 857 706 2604**

**(Registrant's Telephone Number, Including Area Code)**

**Not Applicable**

**(Former name or former address, if changed since last report)**

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

<b>Title of each class</b>	<b>Symbol(s)</b>	<b>on which registered</b>
<b>American Depositary Shares, each representing 10 Ordinary Shares, par value \$0.000006 per share</b>	<b>ZLAB</b>	<b>The Nasdaq Global Market</b>
<b>Ordinary Shares, par value \$0.000006 per share*</b>	<b>9688</b>	<b>The Stock Exchange of Hong Kong Limited</b>

\* Included in connection with the registration of the American Depositary Shares with the Securities and Exchange Commission. The ordinary shares are not registered or listed for trading in the United States but are listed for trading on The Stock Exchange of Hong Kong Limited

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On June 11, 2024, Zai Lab Limited (the “Company”) announced that Dr. Harald Reinhart, President, Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases, has informed the Company that he has decided to retire, effective June 30, 2024. There were no disagreements between Dr. Reinhart and the Company relating to the Company’s operations, policies, or practices that resulted in his decision to retire. Dr. Reinhart will continue to serve as a senior advisor to the Company.

**Item 7.01 Regulation FD Disclosure.**

On June 11, 2024, the Company also announced that Dr. Rafael Amado, President, Head of Global Oncology Research and Development, will be expanding his role to President, Head of Global Research and Development, effective upon Dr. Reinhart’s retirement on June 30, 2024.

A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

**(d) Exhibits**

<u>Exhibit No.</u>	<u>Description</u>
99.1	<a href="#">Press Release issued by Zai Lab Limited on June 11, 2024</a>
104	The cover page of this Current Report on Form 8-K is formatted in Inline XBRL

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

### ZAI LAB LIMITED

By: /s/ F. Ty Edmondson

\_\_\_\_\_

F. Ty Edmondson

Chief Legal Officer and Corporate Secretary

Date: June 11, 2024



**Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D**

SHANGHAI and CAMBRIDGE, Mass., June 11, 2024 – Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) announced today that following a distinguished career, Harald Reinhart, M.D., President, Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases (NSAiID) of Zai Lab, will retire at the end of June, after which he will serve as a senior advisor for the Company. Rafael Amado, M.D., President, Head of Global Oncology Research and Development of Zai Lab, will expand his role and assume responsibility for all of the Company’s Global R&D upon Dr. Reinhart’s retirement.

“Harald has devoted nearly 50 years to treating patients, first as a physician and later discovering and developing innovative therapies to bring to patients in need around the world,” said Dr. Samantha Du, Founder, Chairperson, and Chief Executive Officer of Zai Lab. “Harald joined Zai Lab 10 years ago bringing his experience in infectious diseases and later significantly expanding the Company’s capabilities in autoimmune and neuroscience.”

Dr. Du continued, “It has been a pleasure to work alongside Harald, and we wish him well in his retirement. He has built a strong team and solid foundation that will continue to grow under Rafael’s leadership.”

Dr. Reinhart said, “It’s been a great honor to work with such a talented and dedicated team. I’m very proud of our accomplishments, delivering and developing novel treatments in NSAiID. I look forward to Zai’s continued success.”

As Head of Global R&D, Dr. Amado will continue to advance Zai Lab’s existing and future pipelines across all therapy areas. He has held senior positions and advisory roles in pharmaceutical and biotechnology companies where he was responsible for the discovery and development of a variety of products, across modalities and therapeutic areas.

**About Zai Lab**

Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, autoimmune disorders, infectious disease and neuroscience. Our goal is to leverage our competencies and resources to positively impact human health in China and worldwide.

For additional information about Zai Lab, please visit [www.zailaboratory.com](http://www.zailaboratory.com) or follow us at [www.twitter.com/ZaiLab\\_Global](https://www.twitter.com/ZaiLab_Global).

**Zai Lab Forward-Looking Statements**

This press release contains forward-looking statements about future expectations, plans, and prospects, including, without limitation, statements relating to the prospects and plans for Zai Lab’s management, operations, and growth potential. All statements, other than statements of historical fact, included in this press release are forward-looking statements, and can be identified by words such as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “possible,” “potential,” “will,” “would,” and other similar expressions. Such statements constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees or assurances of future performance. Forward-looking statements are based on our expectations and assumptions as of the date of this press release and are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements. We may not actually achieve the plans, carry out the intentions, or meet the expectations or projections disclosed in our forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by forward-looking statements as a result of various important factors, including but not limited to (1) our ability to successfully commercialize and generate revenue from our approved products, (2) our ability to obtain funding for our operations and business initiatives, (3) the results of our clinical and pre-clinical development of our product candidates, (4) the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approvals of our product candidates, (5) risks related to doing business

in China, and (6) other factors identified in our most recent annual and quarterly reports and in other reports we have filed with the U.S. Securities and Exchange Commission (SEC). We anticipate that subsequent events and developments will cause our expectations and assumptions to change, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Our SEC filings can be found on our website at [www.zailaboratory.com](http://www.zailaboratory.com) and on the SEC's website at [www.sec.gov](http://www.sec.gov).

**For more information, please contact:**

**Investor Relations:**

Christine Chiou / Lina Zhang  
+1 (917) 886-6929 / +86 136 8257 6943  
[christine.chiou1@zailaboratory.com](mailto:christine.chiou1@zailaboratory.com) / [lina.zhang@zailaboratory.com](mailto:lina.zhang@zailaboratory.com)

**Media:**

Shaun Maccoun / Xiaoyu Chen  
+1 (857) 270-8854 / +86 185 0015 5011  
[shaun.maccoun@zailaboratory.com](mailto:shaun.maccoun@zailaboratory.com) / [xiaoyu.chen@zailaboratory.com](mailto:xiaoyu.chen@zailaboratory.com)



Zai Lab Limited